Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Receivables - Net (2020 - 2023)

Historic Receivables - Net for SAB Biotherapeutics (SABS) over the last 4 years, with Q2 2023 value amounting to $364117.0.

  • SAB Biotherapeutics' Receivables - Net fell 9621.21% to $364117.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $364117.0, marking a year-over-year decrease of 9621.21%. This contributed to the annual value of $5.6 million for FY2022, which is 3063.56% down from last year.
  • As of Q2 2023, SAB Biotherapeutics' Receivables - Net stood at $364117.0, which was down 9621.21% from $763123.0 recorded in Q1 2023.
  • In the past 5 years, SAB Biotherapeutics' Receivables - Net ranged from a high of $20.6 million in Q4 2020 and a low of $364117.0 during Q2 2023
  • Over the past 4 years, SAB Biotherapeutics' median Receivables - Net value was $8.8 million (recorded in 2021), while the average stood at $8.7 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Receivables - Net tumbled by 3063.56% in 2022, and later tumbled by 9621.21% in 2023.
  • Quarter analysis of 4 years shows SAB Biotherapeutics' Receivables - Net stood at $20.6 million in 2020, then crashed by 61.06% to $8.0 million in 2021, then plummeted by 30.64% to $5.6 million in 2022, then tumbled by 93.45% to $364117.0 in 2023.
  • Its last three reported values are $364117.0 in Q2 2023, $763123.0 for Q1 2023, and $5.6 million during Q4 2022.